Streetbeat News

Revenues

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) received mixed analyst ratings with a general downward trend in price targets. The average 12-month price target is now $128.79, down 15.39% from the previous $152.22. Analysts' actions included maintaining, raising, and lowering ratings and price targets. Sarepta focuses on developing drugs for rare diseases using RNA-targeted technology and has shown a 44.1% revenue growth rate but faces challenges with market capitalization, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 4:00 pm

IVZ

Invesco (NYSE:IVZ) has received mixed ratings from 8 analysts in the last three months, with an average 12-month price target of $16.62, up 12.37% from the previous target. Analysts from firms including UBS, TD Cowen, RBC Capital, Keefe, Bruyette & Woods, Goldman Sachs, JP Morgan, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's performance and market conditions. Invesco, an investment-management service provider with $1.451 trillion in AUM, faces challenges with below-industry-average revenue growth, net margin, ROE, and ROA, but has a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 3:01 pm

RLJ

RLJ Lodging (NYSE:RLJ) has received mixed analyst ratings over the past three months, with a total of 5 analysts offering their perspectives. The recent ratings show a shift towards a more bullish outlook, with the average 12-month price target now at $13.7, an 11.11% increase from the previous average of $12.33. Analysts from Wolfe Research, Oppenheimer, Truist Securities, and Wells Fargo have provided ratings ranging from 'Outperform' to 'Equal-Weight' and adjusted their price targets accordingly. RLJ Lodging Trust is a real estate investment trust with a portfolio of hotels under major brands, and it has shown positive revenue growth and strong profitability metrics such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 3:01 pm

RBC

RBC Bearings (NYSE:RBC) has received mixed analyst ratings over the past three months, with a total of 4 bullish and 1 indifferent rating. Recent price target updates show a positive trend, with the average 12-month price target raised to $271.2, up 9.35% from the previous $248.00. Analysts from Truist Securities, Goldman Sachs, B of A Securities, and Wells Fargo have adjusted their price targets, reflecting their response to RBC Bearings' market dynamics and performance. RBC Bearings manufactures precision bearings for industrial and aerospace markets, with a focus on the US. Financial indicators show a positive revenue trend but below-average growth rate, high net margin, and below-industry-average ROE and ROA. The company's debt-to-equity ratio is below industry norms.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 3:01 pm

ISRG

Intuitive Surgical Inc (NASDAQ:ISRG) reported preliminary Q4 revenue of $1.93 billion, surpassing consensus estimates of $1.87 billion. The company expects FY23 revenue of $7.12 billion, slightly above estimates of $7.07 billion. Q4 da Vinci procedures grew by 21% Y/Y, with full-year procedures up by 22%. Intuitive Surgical placed 415 da Vinci systems in Q4, a 12% Y/Y increase, and 1,370 systems in 2023, an 8% Y/Y increase. Growth was driven by U.S. general surgery and international cancer procedures. William Blair predicts strong growth into 2024, with potential for the company to exceed its conservative guidance. ISRG shares rose 6.55% to $352.22.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 2:40 pm

PSHZF

Bill Ackman has raised objections to a Business Insider article accusing his wife, Neri Oxman, of academic plagiarism, prompting parent company Axel Springer to review the editorial process behind the article. This marks a departure from Axel Springer's typically hands-off approach to editorial control since acquiring Business Insider. The situation has caused tension within BI's newsroom and with its union, as Axel Springer is a German media group looking to expand in the U.S. Ackman suggested the article may be retaliatory for his criticism of Harvard University and questioned BI's motives, leading to Axel Springer's top executives' concern over the company's principles.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 2:36 pm

MMM

3M Health Care's Medical Solutions Division received a $34.2 million award from the U.S. Army Medical Research Acquisition Activity to develop advanced wound care solutions. The program aims to improve treatment from point-of-injury to hospital, focusing on infection prevention, wound management, and healing in austere settings. 3M will collaborate with the University of Minnesota Medical School, 59MDW/ST, NAMRU-SA, and UT Health San Antonio. The funding supports product development and clinical studies for product registration over 2023-2027.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:18 pm

IPA

ImmunoPrecise Antibodies (NASDAQ:IPA) reported a 19.9% year-over-year revenue increase for the six-month period ending October 31, 2023, with Q2 FY2024 revenues reaching CAD$6.2 million. The company's growth is attributed to its AI-driven biotherapeutic research and technology, including the LENSai platform by its AI subsidiary, BioStrand. IPA's expansion strategy and innovative approach in the biopharmaceutical industry, leveraging Vertical AI and wet lab technologies, have led to consistent revenue growth, with significant contributions from its Canadian laboratory and Dutch manufacturing facility.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:14 pm

SATS

DISH Wireless, a subsidiary of EchoStar Corporation, has been awarded a $50 million grant by the U.S. Department of Commerce. This grant is aimed at supporting the development and deployment of advanced wireless services, which could enhance DISH Wireless's capabilities and market position.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:11 pm

SYF

Synchrony (NYSE:SYF) has renewed its multi-year partnership with The Good Feet Store, continuing to offer its CareCredit card as a payment option for customers seeking arch support products. The partnership, which began in 2009, has been beneficial, with a 10% increase in average transaction total and a 35% increase in total transactions for The Good Feet Store in 2023. Additionally, 30% of The Good Feet Store's sales were from existing CareCredit cardholders. The partnership aims to provide flexible financing options to customers, contributing to their health and wellness.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:11 pm